Dabigatran  	Dabigatran  	 NNP	B-NP
as  	as  	 IN	O
an  	an  	 DT	O
alternative  	alternative  	 NN	O
to  	to  	 TO	O
warfarin  	warfarin  	 VB	O
for  	for  	 IN	O
the  	the  	 DT	O
prevention  	prevention  	 NN	O
of  	of  	 IN	O
thromboembolism  	thromboembolism  	 FW	B-NP
in  	in  	 FW	O
atrial  	atrial  	 FW	B-NP
fibrillation  	fibrillation  	 FW	I-NP
Atrial  	Atrial  	 FW	I-NP
fibrillation  	fibrillation  	 FW	I-NP
( 	( 	 -LRB-	O
AF 	AF 	 NNP	B-NP
)  	)  	 -RRB-	O
is  	is  	 VBZ	O
an  	an  	 DT	O
independent  	independent  	 JJ	O
major  	major  	 JJ	O
risk  	risk  	 NN	B-NP
factor  	factor  	 NN	I-NP
for  	for  	 IN	O
stroke 	stroke 	 NN	O
,  	,  	 ,	O
and  	and  	 CC	O
antithrombotic  	antithrombotic  	 JJ	B-NP
therapy  	therapy  	 NN	I-NP
is  	is  	 VBZ	O
here  	here  	 RB	O
recommended  	recommended  	 VBN	O
according  	according  	 VBG	O
to  	to  	 TO	O
stratification  	stratification  	 VB	B-NP
of  	of  	 IN	O
the  	the  	 DT	O
patient 	patient 	 NN	O
's  	's  	 POS	O
thromboembolic  	thromboembolic  	 NN	B-NP
and  	and  	 CC	O
hemorrhagic  	hemorrhagic  	 JJ	B-NP
risks 	risks 	 NNS	I-NP
.  	.  	 .	O
Recent  	Recent  	 JJ	B-NP
evidence  	evidence  	 NN	I-NP
is  	is  	 VBZ	O
leading  	leading  	 VBG	O
to  	to  	 TO	O
the  	the  	 DT	O
replacement  	replacement  	 NN	O
of  	of  	 IN	O
vitamin  	vitamin  	 JJ	B-NP
K  	K  	 NN	I-NP
antagonists 	antagonists 	 NNS	I-NP
,  	,  	 ,	O
the  	the  	 DT	O
efficacy  	efficacy  	 NN	O
of  	of  	 IN	O
which  	which  	 WDT	O
in  	in  	 IN	O
preventing  	preventing  	 VBG	B-NP
stroke  	stroke  	 NN	I-NP
in  	in  	 IN	O
AF  	AF  	 NNP	B-NP
is  	is  	 VBZ	O
well  	well  	 RB	O
established 	established 	 VBN	O
,  	,  	 ,	O
with  	with  	 IN	O
better  	better  	 JJR	O
tolerated  	tolerated  	 NNS	O
and  	and  	 CC	O
more  	more  	 RBR	O
manageable  	manageable  	 JJ	O
new  	new  	 JJ	O
anticoagulant  	anticoagulant  	 JJ	B-NP
drugs 	drugs 	 NNS	I-NP
,  	,  	 ,	O
with  	with  	 IN	O
a  	a  	 DT	O
lower  	lower  	 JJR	O
risk  	risk  	 NN	O
of  	of  	 IN	O
intracranial  	intracranial  	 JJ	B-NP
bleeding 	bleeding 	 NN	I-NP
,  	,  	 ,	O
no  	no  	 DT	O
clear  	clear  	 JJ	O
interactions  	interactions  	 NNS	B-NP
with  	with  	 IN	O
food 	food 	 NN	O
,  	,  	 ,	O
fewer  	fewer  	 JJR	O
interactions  	interactions  	 NNS	B-NP
with  	with  	 IN	O
medications 	medications 	 NN	O
,  	,  	 ,	O
and  	and  	 CC	O
no  	no  	 DT	O
need  	need  	 NN	O
for  	for  	 IN	O
frequent  	frequent  	 JJ	O
laboratory  	laboratory  	 NN	O
monitoring  	monitoring  	 NN	O
and  	and  	 CC	O
dose  	dose  	 NN	O
adjustments 	adjustments 	 NNS	O
.  	.  	 .	O
Among  	Among  	 IN	O
new  	new  	 JJ	O
anticoagulants 	anticoagulants 	 NN	B-NP
,  	,  	 ,	O
dabigatran  	dabigatran  	 JJ	B-NP
etexilate  	etexilate  	 NN	I-NP
is  	is  	 VBZ	O
a  	a  	 DT	O
direct 	direct 	 JJ	O
,  	,  	 ,	O
competitive  	competitive  	 JJ	B-NP
inhibitor  	inhibitor  	 NN	I-NP
of  	of  	 IN	I-NP
thrombin 	thrombin 	 NN	I-NP
.  	.  	 .	O
It  	It  	 PRP	O
was  	was  	 VBD	O
evaluated  	evaluated  	 VBN	O
for  	for  	 IN	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
AF  	AF  	 NNP	B-NP
in  	in  	 IN	O
the  	the  	 DT	O
RE-LY  	RE-LY  	 JJ	B-NP
trial 	trial 	 NN	I-NP
,  	,  	 ,	O
showing  	showing  	 VBG	O
lower  	lower  	 JJR	O
rates  	rates  	 NNS	O
of  	of  	 IN	O
stroke  	stroke  	 NN	O
and  	and  	 CC	O
systemic  	systemic  	 JJ	B-NP
embolism  	embolism  	 NN	I-NP
at  	at  	 IN	O
a  	a  	 DT	O
dose  	dose  	 NN	O
of  	of  	 IN	O
150  	150  	 CD	O
mg  	mg  	 NNS	B-NP
twice  	twice  	 RB	O
daily  	daily  	 JJ	O
with  	with  	 IN	O
similar  	similar  	 JJ	O
rates  	rates  	 NNS	O
of  	of  	 IN	O
major  	major  	 JJ	O
hemorrhage  	hemorrhage  	 NNS	B-NP
compared  	compared  	 VBN	O
with  	with  	 IN	O
warfarin 	warfarin 	 NNS	B-NP
;  	;  	 :	O
and  	and  	 CC	O
non-inferiority  	non-inferiority  	 JJ	B-NP
compared  	compared  	 VBN	O
with  	with  	 IN	O
warfarin  	warfarin  	 NN	B-NP
for  	for  	 IN	O
the  	the  	 DT	O
prevention  	prevention  	 NN	O
of  	of  	 IN	O
stroke  	stroke  	 NN	O
and  	and  	 CC	O
systemic  	systemic  	 JJ	B-NP
embolism  	embolism  	 NN	I-NP
at  	at  	 IN	O
a  	a  	 DT	O
dose  	dose  	 NN	O
of  	of  	 IN	O
110  	110  	 CD	O
mg  	mg  	 NNS	B-NP
twice  	twice  	 RB	O
daily 	daily 	 RB	O
,  	,  	 ,	O
with  	with  	 IN	O
lower  	lower  	 JJR	O
rates  	rates  	 NNS	O
of  	of  	 IN	O
major  	major  	 JJ	O
bleeding 	bleeding 	 NN	O
.  	.  	 .	O
Beside  	Beside  	 IN	O
dabigatran 	dabigatran 	 NN	B-NP
,  	,  	 ,	O
oral  	oral  	 JJ	B-NP
factor  	factor  	 NN	I-NP
Xa  	Xa  	 NNP	I-NP
inhibitors  	inhibitors  	 NNS	I-NP
are  	are  	 VBP	O
also  	also  	 RB	O
emerging  	emerging  	 VBG	O
for  	for  	 IN	O
the  	the  	 DT	O
prevention  	prevention  	 NN	O
of  	of  	 IN	O
thromboembolic  	thromboembolic  	 JJ	B-NP
events  	events  	 NNS	I-NP
in  	in  	 IN	O
AF 	AF 	 NNP	B-NP
.  	.  	 .	O
Despite  	Despite  	 IN	O
the  	the  	 DT	O
obvious  	obvious  	 JJ	O
advantages  	advantages  	 NNS	O
of  	of  	 IN	O
these  	these  	 DT	O
new  	new  	 JJ	O
oral  	oral  	 JJ	B-NP
anticoagulants  	anticoagulants  	 NN	I-NP
over  	over  	 IN	O
vitamin  	vitamin  	 JJ	B-NP
K  	K  	 NN	I-NP
antagonists 	antagonists 	 NNS	I-NP
,  	,  	 ,	O
further  	further  	 JJ	O
information  	information  	 NN	O
is  	is  	 VBZ	O
still  	still  	 RB	O
needed  	needed  	 VBN	O
on  	on  	 IN	O
how  	how  	 WRB	O
to  	to  	 TO	O
prioritize  	prioritize  	 VB	O
the  	the  	 DT	O
patients  	patients  	 NNS	O
deriving  	deriving  	 VBG	O
the  	the  	 DT	O
greatest  	greatest  	 JJS	O
benefit  	benefit  	 NN	O
from  	from  	 IN	O
these  	these  	 DT	O
novel  	novel  	 NN	O
agents  	agents  	 NNS	O
on  	on  	 IN	O
the  	the  	 DT	O
basis  	basis  	 NN	O
of  	of  	 IN	O
patient  	patient  	 JJ	O
characteristics  	characteristics  	 NNS	O
or  	or  	 CC	O
drug  	drug  	 NN	B-NP
pharmacokinetics 	pharmacokinetics 	 NN	I-NP
.  	.  	 .	O
There  	There  	 EX	O
is  	is  	 VBZ	O
also  	also  	 RB	O
a  	a  	 DT	O
need  	need  	 NN	O
for  	for  	 IN	O
assessing  	assessing  	 VBG	O
their  	their  	 PRP$	O
long-term  	long-term  	 JJ	O
efficacy  	efficacy  	 NN	O
and  	and  	 CC	O
safety  	safety  	 NN	O
over  	over  	 IN	O
decades  	decades  	 NNS	O
in  	in  	 IN	O
the  	the  	 DT	O
real-world  	real-world  	 JJ	B-NP
setting 	setting 	 NN	I-NP
.  	.  	 .	O
